Recent trading + Gains + Superb RNS14 Jan 2023 07:53
Morning All
What a superb 10 sessions for all invested & bagged a superb RNS to lite the blue touch paper with plenty more news in the pipeline .
If you go back a week before the RNS
Stock price - 1.35 & by end of pre week 1.8 p plenty of pre RNS buying in my eyes
These kippers landed on the 5 th a week before the RNS & volume picked up to 20 million
05-Jan-23 14:43:57 1.949 770,240 Buy* 1.90 1.95 15.01k O
05-Jan-23 14:40:37 1.925 854,793 Buy* 1.85 1.95 16.45k O
This buy on the 4 th & stock started shifting north + vol picked up
04-Jan-23 16:15:08 1.60 1,000,000 Buy* 1.55 1.60 16.00k O
If you were market sceptical as I am , you could say some new the RNS was incoming as multiple buys & vol increase the week before the RNS landed .
Market shenanigans as usual , the trick for private investors is to beat them to it by holding onto your stock & add on dips imo .
RNS day -
This part taken from Ortex news after mondays RNS , is certainly a potential stock shifter & mind boggling for the fight against cancer .
‘We are pleased now to be announcing further exciting developments in our CBR platform. CBR is a ground-breaking new approach to treat existing and emerging viral infections as well as potentially becoming an effective new form of cancer treatment," said Chief Executive Officer Vladislav Sandler.’
Stock price 2.3p
Vol 33 million
Average vol 5 million
Midweek
Stock price 2.8
Vol 44 million
Yesterday close
3.5 p
Volume- 81 million ( 3 yr high )
MCap 35 million
Stock on loan / shorts
100k
Available stock on loan - 1 m
Very little interest in shorting this stock - another positive
Relentless buying all week with buys outstripping sells 2> 1 all week - hence
Stock gained
50% pre RNS
After RNS 130%
Total gains for 2023 + 180%
& still gaining 5 sessions after the RNS .
All looking great for all invested & on the road to clinical trials which is the big stock mover according to Vlad & I certainly agree imo .
Another superb section from Mondays RNS -
Hemogenyx said that its scientists have identified a target protein that can be incorporated into a single multi-purpose CBR-based therapeutic, replacing the need to produce a separate CBR construct for every virus.
Among the viruses are Dengue, Ebola, Marburg, Zika, and Chikungunya.
Bring on 2023 Hemo with the great work done & potentially give all invested the stock price to match the breakthrough science.
Saturday coffees all round
Sign In
Follow the stocks
